跳到主要内容
Learn Motion
探索课程产品能力价格

下载 Learn Motion

用手机扫描二维码,下载 App。

App Store

扫码从 App Store 下载 Learn Motion打开商店页面

Google Play

扫码从 Google Play 下载 Learn Motion打开商店页面
登录
Learn Motion

How AI Predicts Drug Failure Before Human Trials

1Why Predicting Drug Failure Matters2What AI Learns From: The Data Behind Predictions3How AI Turns Data Into a Failure Prediction4Judging Whether a Prediction Can Be Trusted5How Predictions Are Used in Real Drug Development
What AI Learns From: The Data Behind Predictions

Four Kinds of Evidence About a Drug

1 / 3
Think of the prediction node in the center as the question we want answered: will this drug fail? Four streams feed into it, and each one answers a different part of that question. Structure tells us what the molecule is. Assay data tells us how it behaves in a biological setting. Trial history tells us what happened to drugs like it in real people. Real-world and literature data fill in what controlled studies never tested. Notice that the map is not four alternatives — it is four partial views of the same candidate. Where all four agree, the prediction has something solid to stand on. Where one stream is thin or missing, the center node is being fed by less than it appears to be.
0:00 / 0:00

A prediction about a drug is assembled from four broad kinds of evidence, each answering a different question about the same candidate.

Molecular structure is the drug's chemical identity: the atoms and the shape they form. It answers what the molecule is, and it is available very early, often before the drug has been tested in anything living.

Biological and assay data describe how the drug behaves in a biological setting — how tightly it binds to its intended target, what it does to cells in a dish, how it is broken down, and whether it disturbs unrelated biology. This is measured, not inferred, and it is where a promising molecule starts to look risky.

Historical trial outcomes record what happened when past drugs were actually given to people: whether they worked, whether they were safe, and at what stage they were abandoned. This is the only category that captures the endpoint the prediction is trying to anticipate.

Real-world and literature data add the wider context — reports of side effects after a drug reaches the market, published studies, and clinical records. It is messier than the first three, but it covers situations no controlled study was designed to test.

No single category is sufficient. Structure alone says nothing about safety; assay results alone say nothing about whether a drug will survive contact with a real patient population. A prediction is strongest where these four sources agree, and weakest where one of them is thin.

上一页1 / 3下一页

Learn Motion

生成课程,认真学会。

运营方:Wuhan Daoyin Technology Co., Ltd.

联系我们: [email protected]
隐私政策用户服务协议

© 2026 Learn Motion